Drug and Therapeutics Bulletin 2007;45:41-44; doi:10.1136/dtb.2007.45641
Copyright © 2007 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Less weight or more hype with {blacktriangledown}rimonabant?

Relevant BNF section: 4.5

{blacktriangledown}Rimonabant (Acomplia – Sanofi-Aventis) has been licensed in the UK since June 2006 for the treatment of obese and certain overweight adults. Advertisements claim the drug has beneficial effects on "cardiometabolic risk factors", and that "an estimated 50% of the effects...on cardiometabolic risk factors are beyond those expected from weight loss alone". Here we review the role of rimonabant in managing patients with obesity.




This article has been cited by other articles:


Home page
 DTBHome page
Surgery for obesity in adults
DTB, June 1, 2008; 46(6): 41 - 45.
[Abstract] [Full Text] [PDF]


About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2007 BMJ Publishing Group Ltd.